Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C44H69NO12.H2O |
Molecular Weight | 822.0334 |
Optical Activity | ( - ) |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]2OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)OC
InChI
InChIKey=NWJQLQGQZSIBAF-MLAUYUEBSA-N
InChI=1S/C44H69NO12.H2O/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7;/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3;1H2/b25-19+,27-21+;/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+;/m0./s1
Molecular Formula | C44H69NO12 |
Molecular Weight | 804.0182 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 14 / 14 |
E/Z Centers | 1 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Tacrolimus, previously known as FK506, is the active ingredient in Prograf. Tacrolimus is a macrolide immunosuppressant produced by Streptomyces tsukubaensis. It reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP-12 (FK506 binding protein) creating a new complex. This FKBP12-FK506 complex interacts with and inhibits calcineurin thus inhibiting both T-lymphocyte signal transduction and IL-2 transcription. Tacrolimus inhibits T-lymphocyte activation, although the exact mechanism of action is not known. Experimental evidence suggests that tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin is then formed and the phosphatase activity of calcineurin inhibited. This effect may prevent the dephosphorylation and translocation of nuclear factor of activated T-cells (NF-AT), a nuclear component thought to initiate gene transcription for the formation of lymphokines (such as interleukin-2, gamma interferon). The net result is the inhibition of T-lymphocyte activation (i.e., immunosuppression). Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver transplants, kidney transplants, heart transplants. It has also been used in a topical preparation in the treatment of severe atopic dermatitis.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1902 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16289353 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | PROGRAF Approved UsePrograf is a calcineurin-inhibitor immunosuppressant indicated for: Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants. Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) Launch Date1994 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
6.2 ng/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TACROLIMUS blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
26 ng/mL |
0.2 mg/kg 1 times / day multiple, oral dose: 0.2 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TACROLIMUS blood | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
74 ng × h/mL |
4 mg 1 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TACROLIMUS blood | Homo sapiens population: HEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
|
372 ng × h/mL |
0.2 mg/kg 1 times / day multiple, oral dose: 0.2 mg/kg route of administration: Oral experiment type: MULTIPLE co-administered: |
TACROLIMUS blood | Homo sapiens population: UNHEALTHY age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Disc. AE: Anemia, Edema lung... AEs leading to discontinuation/dose reduction: Anemia Sources: Edema lung Allergic reaction Abnormal liver function tests Bilirubinemia Lymphoma like reaction Diarrhea Intestinal obstruction |
5.2 mg 1 times / day multiple, oral Highest studied dose Dose: 5.2 mg, 1 times / day Route: oral Route: multiple Dose: 5.2 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
8 mg single, oral Highest studied dose Dose: 8 mg Route: oral Route: single Dose: 8 mg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
0.1 mg/kg 2 times / day multiple, oral Recommended Dose: 0.1 mg/kg, 2 times / day Route: oral Route: multiple Dose: 0.1 mg/kg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Other AEs: Infection... Other AEs: Infection (serious) Sources: |
0.02 mg/kg single, intravenous Dose: 0.02 mg/kg Route: intravenous Route: single Dose: 0.02 mg/kg Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
|
0.03 % 1 times / day multiple, topical Dose: 0.03 %, 1 times / day Route: topical Route: multiple Dose: 0.03 %, 1 times / day Sources: |
unhealthy |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Abnormal liver function tests | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Allergic reaction | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Anemia | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Bilirubinemia | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Diarrhea | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Edema lung | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Intestinal obstruction | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Lymphoma like reaction | Disc. AE | 0.15 mg/kg 2 times / day steady, oral Dose: 0.15 mg/kg, 2 times / day Route: oral Route: steady Dose: 0.15 mg/kg, 2 times / day Sources: |
unhealthy, 1.9 years (range: 3-15 years) Health Status: unhealthy Age Group: 1.9 years (range: 3-15 years) Sex: M+F Sources: |
Infection | serious | 0.1 mg/kg 2 times / day multiple, oral Recommended Dose: 0.1 mg/kg, 2 times / day Route: oral Route: multiple Dose: 0.1 mg/kg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
no | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | yes (co-administration study) Comment: Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism. Page: - |
||
Page: - |
yes | yes (pharmacogenomic study) Comment: Tacrolimus was metabolized by the cytochrome P450 (CYP) 3A subfamily. Metabolic drug-drug interaction studies were conducted to provide information regarding the optimal usage of tacrolimus, and its metabolism was inhibited by known CYP3A inhibitors such as ketoconazole, cyclosporine A, and nifedipine. Recent reports on clinical pharmacokinetics indicate that dose levels of tacrolimus need to be adjusted in transplant patients with CYP3A5 polymorphism. Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
Neurotoxicity after orthotopic liver transplantation in cyclosporin A- and FK 506-treated patients. | 1994 |
|
Renal complications and development of hypertension in the European study of FK 506 and cyclosporin in primary liver transplant recipients. | 1994 |
|
Tacrolimus toxicity in rhesus monkey: model for clinical side effects. | 1999 Dec |
|
Rapamycin inhibits didemnin B-induced apoptosis in human HL-60 cells: evidence for the possible involvement of FK506-binding protein 25. | 1999 Jun |
|
Calcineurin and vacuolar-type H+-ATPase modulate macrophage effector functions. | 1999 May 25 |
|
Leg bone pain syndrome in a kidney transplant patient treated with tacrolimus (FK506). | 1999 Oct |
|
Neuronal survival activity of s100betabeta is enhanced by calcineurin inhibitors and requires activation of NF-kappaB. | 1999 Sep |
|
Tacrolimus in acute renal failure: does L-arginine-infusion prevent changes in renal hemodynamics? | 2000 |
|
Arteriolopathy in non-episode biopsies of renal transplant allograft. | 2000 |
|
Co-administration of furosemide augments tacrolimus-induced impairment in kidney function in rats. | 2000 |
|
Treatment of tacrolimus-related adverse effects by conversion to cyclosporine in liver transplant recipients. | 2000 |
|
Reversible tacrolimus-induced neurotoxicity isolated to the brain stem. | 2000 Aug |
|
Suppressive effects of cyclosporin A and FK-506 on superoxide generation in human polymorphonuclear leukocytes primed by tumor necrosis factor alpha. | 2000 Dec |
|
Sirolimus in pediatric gastrointestinal transplantation: the use of sirolimus for pediatric transplant patients with tacrolimus-related cardiomyopathy. | 2000 Feb |
|
Conversion to neoral for neurotoxicity after primary adult liver transplantation under tacrolimus. | 2000 Jan 15 |
|
Caspase-mediated proteolytic activation of calcineurin in thapsigargin-mediated apoptosis in SH-SY5Y neuroblastoma cells. | 2000 Jul 15 |
|
Effect of aminophylline on urine flow in children with tacrolimus-induced renal insufficiency. | 2000 Jun |
|
Cortical laminar necrosis caused by immunosuppressive therapy and chemotherapy. | 2000 Mar |
|
FK506 inhibition of histamine release and cytokine production by mast cells and basophils. | 2000 Mar |
|
Immunosuppressive drugs: the first 50 years and a glance forward. | 2000 May |
|
Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. | 2000 Nov |
|
Fatal cerebral hemorrhage associated with cyclosporin-A/FK506-related encephalopathy after allogeneic bone marrow transplantation. | 2000 Oct |
|
Cyclosporine and tacrolimus-associated thrombotic microangiopathy. | 2000 Oct |
|
Conversion to rapamycin immunosuppression in renal transplant recipients: report of an initial experience. | 2000 Oct 27 |
|
Delayed transient neurologic toxicity due to tacrolimus: CT and MRI. | 2000 Sep |
|
Tacrolimus-associated mutism after orthotopic liver transplantation. | 2000 Sep 27 |
|
[Acute peripheral demyelinating polyneuropathy and acute renal failure after administration of FK506]. | 2001 |
|
Calcineurin-inhibitor related nephrotoxicity- reversibility in paediatric liver transplant recipients. | 2001 Aug 27 |
|
End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. | 2001 Dec 27 |
|
Sirolimus interferes with the innate response to bacterial products in human whole blood by attenuation of IL-10 production. | 2001 Feb |
|
Mycophenolate mofetil monotherapy in liver transplantation. | 2001 Feb 24 |
|
Targeting keratinocyte apoptosis in the treatment of atopic dermatitis and allergic contact dermatitis. | 2001 Nov |
|
Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 Nov 27 |
|
Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. | 2001 Oct |
|
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus. | 2001 Oct |
|
Expression of TGF-beta and fibrogenic genes in transplant recipients with tacrolimus and cyclosporine nephrotoxicity. | 2002 Dec |
|
Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. | 2002 Jul 19 |
|
FK 506-induced fulminant leukoencephalopathy after kidney transplantation: case report. | 2002 Jun |
|
Downregulation of both interleukin-12 and interleukin-2 in heart allografts by pretransplant host treatment with granulocyte colony-stimulating factor and tacrolimus. | 2002 May 7 |
|
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. | 2002 Oct |
|
Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. | 2002 Sep |
|
Neuropsychologic side-effects of tacrolimus in pediatric renal transplantation. | 2003 Apr |
|
Speech disorder related to tacrolimus-induced pontine myelinolysis after orthotopic liver transplantation. | 2003 Aug |
|
Treatment of human T cells with bisperoxovanadium phosphotyrosyl phosphatase inhibitors leads to activation of cyclooxygenase-2 gene. | 2003 Feb 28 |
|
Steroid-free immunosuppression during and after liver transplantation--a 3-yr follow-up report. | 2003 Jun |
|
Microangiopathic haemolytic anaemia and thrombocytopenia following lung volume reduction surgery in a single lung transplant recipient on maintenance tacrolimus (FK506) therapy. | 2003 Jun |
|
Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. | 2003 Mar |
|
The immunophilin-ligands FK506 and V-10,367 mediate neuroprotection by the heat shock response. | 2003 Mar |
|
Enhanced interleukin-4 production in CD4+ T cells and elevated immunoglobulin E levels in antigen-primed mice by bisphenol A and nonylphenol, endocrine disruptors: involvement of nuclear factor-AT and Ca2+. | 2003 May |
|
MR imaging with quantitative diffusion mapping of tacrolimus-induced neurotoxicity in organ transplant patients. | 2003 May |
Patents
Sample Use Guides
Dosage in Adult Kidney, Liver, or Heart Transplant Patients:
Adult kidney transplant patients (Oral Dosage: daily doses should be administered as two divided doses, every 12 hours): in combination with azathioprine: 0.2 mg/kg/day; in combination with MMF/IL-2 receptor antagonist: 0.1 mg/kg/day. Adult liver transplant patients: 0.10-0.15 mg/kg/day. Adult heart transplant patients: 0.075 mg/kg/day.
Prograf (TACROLIMUS) injection should be used only as a continuous IV infusion and when the patient cannot tolerate oral administration of Prograf capsules. Prograf injection should be discontinued as soon as the patient can tolerate oral administration of Prograf capsules, usually within 2-3 days. In a patient receiving an IV infusion, the first dose of oral therapy should be given 8-12 hours after discontinuing the IV infusion. The recommended starting dose of Prograf injection is 0.03-0.05 mg/kg/day in kidney and liver transplant and 0.01 mg/kg/day in heart transplant given as a continuous IV infusion. Adult patients should receive doses at the lower end of the dosing range. Concomitant adrenal corticosteroid therapy is recommended early post-transplantation.
Dosage in Pediatric Liver Transplant Patients: (Oral Dosage): Pediatric liver transplant patients 0.15-0.20 mg/kg/day (daily doses should be administered as two divided doses, every 12 hours)
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25339327
Tacrolimus at concentration of 0.06 μmol/L could promote collagen induced platelet aggregation, inhibit thrombin induced platelet aggregation, have no effect on ristocetin and vWF induced platelet aggregation function. Tacrolimus at concentration of 120 μmol/L and 240 μmol/L could reduce the platelet mitochondrial membrane potential and induce the expression of apoptosis protein caspase-3. In vitro experimental results showed that high concentration of tacrolimus could lead to platelet apoptosis. But the current therapeutic dose of tacrolimus at 0.06 μmol/L (which is equivalent to 50 ng/ml blood concentration) could have different effects on platelet aggregation function according to different stimulating agents.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:08:23 GMT 2025
by
admin
on
Mon Mar 31 18:08:23 GMT 2025
|
Record UNII |
WM0HAQ4WNM
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
472815
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
743220
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
534516
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
WHO-VATC |
QD11AH01
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
407113
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
ADVAGRAF (AUTHORIZED: GRAFT REJECTION)
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
314310
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
LIVERTOX |
NBK548545
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
WHO-ATC |
L04AD02
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
NCI_THESAURUS |
C2201
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
ENVARSUS (AUTHORIZED: GRAFT REJECTION)
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
MODIGRAF (AUTHORIZED: GRAFT REJECTION)
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
468214
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
849321
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
NDF-RT |
N0000175457
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
701319
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
753620
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
203305
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/03/185
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
WHO-ATC |
D11AH01
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
PROTOPIC (AUTHORIZED: PSORIASIS)
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
FDA ORPHAN DRUG |
111398
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
NCI_THESAURUS |
C146638
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
WHO-VATC |
QL04AD02
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
||
|
EMA ASSESSMENT REPORTS |
PROTOPY (AUTHORIZED: DERMATATIS, ATOPIC)
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
758659
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
CHEMBL269732
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
SUB23141
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
C1311
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
2552
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
484288
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
61049
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
TACROLIMUS
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
109581-93-3
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
6784
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
5282315
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
42316
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
ALTERNATIVE | |||
|
100000087996
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
SUB25193
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
DB00864
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
D016559
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
WM0HAQ4WNM
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
Tacrolimus
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
m10425
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | Merck Index | ||
|
DTXSID001350197
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
WM0HAQ4WNM
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
61057
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
1642802
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY | |||
|
EE-43
Created by
admin on Mon Mar 31 18:08:23 GMT 2025 , Edited by admin on Mon Mar 31 18:08:23 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> SUBSTRATE | |||
|
PARENT -> SALT/SOLVATE |
|
||
|
ANHYDROUS->SOLVATE |
|
||
|
TARGET -> INHIBITOR | |||
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
MINOR
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|